Metastatic Colorectal Cancer Market Set for Strong Growth Across the 7MM (2025–2034)
The metastatic colorectal cancer market is on a clear upward trajectory across the seven major markets (7MM), supported by rapid progress in targeted therapies, immunotherapy, and precision medicine. Rising incidence rates of colorectal cancer, combined with improved awareness regarding early screening and evolving treatment strategies, are significantly boosting demand for more effective and tailored therapeutic options. Colorectal cancer (CRC) remains one of the most commonly diagnosed cancers globally, ranking third in prevalence, and metastasis continues to be a major contributor to mortality as the disease spreads beyond the primary tumor site—most commonly to the liver and peritoneum, followed by the lungs and lymph nodes. Despite therapeutic advances, metastatic colorectal cancer (mCRC) is still largely incurable for most patients, with treatment resistance and disease aggressiveness posing persistent clinical challenges. A key factor influencing disease progression is the presence of genetic mutations, particularly KRAS mutations, which occur in nearly 45% of patients and are associated with poorer prognosis and reduced responsiveness to standard therapies.
The epidemiological landscape underscores a growing burden, with approximately 294,000 incident mCRC cases reported across the 7MM in 2024, a number expected to rise steadily through 2034 due to aging populations, lifestyle factors, and improved diagnostics. Treatment strategies depend heavily on disease stage and resectability; while surgery remains the preferred option for resectable tumors, many patients are diagnosed at advanced stages where systemic therapies such as chemotherapy, radiotherapy, and immunotherapy are required.
These approaches can extend survival but often lack precision and may impact healthy tissues. The treatment paradigm spans multiple lines: first-line therapies typically include chemotherapy combinations such as FOLFOX, FOLFIRI, and CAPEOX, often paired with targeted agents like VECTIBIX and ERBITUX or immunotherapies such as KEYTRUDA and BRAFTOVI-based regimens. Second-line options expand to include OPDIVO (with or without YERVOY), JEMPERLI, TUKYSA combinations, LONSURF-based regimens, and KRAZATI combinations, while third-line treatments commonly involve STIVARGA and FRUZAQLA, providing additional disease control options after prior therapy failure.
Learn more about the metastatic colorectal cancer treatment landscape @ Metastatic Colorectal Cancer Drugs Market
Recent approvals are reshaping the treatment landscape, with FRUZAQLA (fruquintinib), an oral VEGFR inhibitor targeting angiogenesis pathways, emerging as a significant advancement for previously treated patients. Its approvals across the United States, Europe, and Japan mark a notable milestone, particularly as the first new targeted therapy for mCRC in Japan in over a decade. Another key innovation is OPDIVO QVANTIG, a subcutaneous formulation combining nivolumab and hyaluronidase for MSI-H or dMMR patients, approved by the FDA in December 2024. This formulation significantly reduces administration time, enhancing patient convenience and clinical efficiency.
To know more about metastatic colorectal cancer treatments, visit @ Metastatic Colorectal Cancer Aggressive Treatment
Despite progress, the market remains highly competitive with significant unmet needs, particularly in achieving durable responses and overcoming resistance. Research efforts are increasingly focused on novel mechanisms and tumor microenvironment modulation, with a robust pipeline of investigational therapies in development. Leading companies such as Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, and Innovative Cellular Therapeutics are actively advancing next-generation treatments. Among emerging candidates, amivantamab, a bispecific antibody targeting EGFR and MET, is currently in Phase III trials, offering dual inhibition of tumor signaling pathways alongside immune activation. Zanzalintinib (XL-092), a third-generation multi-kinase inhibitor targeting VEGF, MET, AXL, and MER pathways, is also progressing through Phase III development. Additionally, DKN-01, targeting the DKK1 protein, is being evaluated in the DeFianCe trial in combination with bevacizumab and chemotherapy, with early results anticipated in 2025.
Discover which therapies are expected to grab major metastatic colorectal cancer drug market share @ Metastatic Colorectal Cancer Market Report
The market outlook remains highly promising, with significant growth expected over the forecast period. According to DelveInsight, the mCRC market across the 7MM was valued at approximately USD 13 billion in 2024 and is projected to expand at a substantial CAGR through 2034, driven by increasing adoption of targeted therapies and immunotherapies that offer improved clinical outcomes. DelveInsight’s comprehensive report, Metastatic Colorectal Cancer Market Insight, Epidemiology, and Market Forecast – 2034, provides detailed analysis of market dynamics, treatment practices, and patient populations, including total incident cases, gender- and age-specific distributions, tumor location, stage-specific segmentation, mutation profiles, and treated cases by therapy line. It also delivers strategic insights such as 10-year forecasts, epidemiology-based market modeling, historical and projected market trends, emerging drug uptake, peak sales analysis, competitive landscape assessment, expert opinions, and access and reimbursement considerations.
Discover more about drugs for metastatic colorectal cancer in development @ Metastatic Colorectal Cancer Clinical Trials
Download this metastatic colorectal cancer market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the metastatic colorectal cancer market. Also, stay abreast of the mitigating factors to improve your market position in the metastatic colorectal cancer therapeutic space.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Related report
Metastatic Colorectal Cancer Epidemiology Forecast - 2034
DelveInsight’s “Metastatic colorectal cancer – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Metastatic colorectal cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Metastatic Colorectal Cancer Companies developing therapies include - Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncology, and others.
Metastatic Colorectal Cancer - Pipeline Insight, 2026
DelveInsight’s, “Metastatic Colorectal Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. The leading Metastatic Colorectal Cancer Companies developing therapies include - Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncology, and others.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com